Hepatocellular carcinoma
Conditions
Interventions
therapy group:Thymosin Alpha 1 (Zadaxin) 1.6mg injection subcutaneously, qd for two days before surgery, tiw for twelve weeks after surgery.
control group:None
Sponsors
Liver Cancer Institute and Zhongshan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. 18 to 75 years old male or non-pregnant female hepatocellular carcinoma patient; 2. Radical resection of HCC (defined as completely removal of the tumor and without macroscopic tumor thrombi) for the first time and without other prior antitumor therepies; 3. Pathologically proved HCC, solitary tumor <3cm or two tumors <5cm in diameter, without extrahepatic metastasis or adjacent organ involvement before surgery; 4. Can understand and complete the informed consent of this study.
Exclusion criteria
Exclusion criteria: 1. With evidence of extrahepatic metastasis, macroscopic tumor thrombi in portal vein, inferior caval vein or intrahepatic bile ducts; 2. Motality within one month after surgery; 3. With evidence of unstable angina pectoris, symptomatic congestive heart failure, severe arrhythmia, acute myocardial infarction within the last six months, prolonged QT interval (>450ms); 4. With evidence of active infection (NCI-CTCAE version 3.0, >grade two); 5. Usage of other anticancer drugs or immuno-modulating drugs; 6. Too poor condition to be tolerated of the drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1-, 2-, 3-year recurrence free survival and recurrence; | — |
Secondary
| Measure | Time frame |
|---|---|
| 1-, 2-, 3-year overall survival; | — |
Countries
China
Contacts
Public ContactJia Fan
Outcome results
None listed